Long-term Observational Study to Evalution the Safety and Efficacy of FURESTEM-AD Inj.

NCT03458624 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2018-03-08

No results posted yet for this study

Summary

Observational Study to Assess the Safety and Efficacy of FURESTEM-AD lnj. In moderate to Atopic Dermatitis

Conditions

Sponsors & Collaborators

  • Kang Stem Biotech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Tae-Yun Kim · Seoul St. Mary's Hospital

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2016-08-12
Completion
2018-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03458624 on ClinicalTrials.gov